Cancer Drug Maker Arcus Surges as Street Touts $10 Billion Opportunity With Gilead [Yahoo! Finance News]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance News
) -- Arcus Biosciences Inc., which is working in a category of new cancer medicines estimated to be worth as much $10 billion, nearly doubled after reported that Gilead Sciences Inc. is in talks to buy a stake in the drug developer.An experimental therapy from Arcus known as AB154 is the likely target of Gilead’s interest, Citigroup Inc. analysts led by Mohit Bansal said. The immune checkpoint inhibitor belongs to a category of medicines known as Tigit that target T-cell immunoreceptors; the class could be a $10 billion annual sales opportunity at peak, according to Citi.Tigit medicines are viewed as “the sequel to the PD-1 blockbuster,” Citi’s analysts said in a research note, alluding to Merck & Co. and Bristol-Myers Squibb Co.’s cancer drugs. Merck’s Keytruda generated over $11 billion in revenue last year.Gilead “still has to prove its strength in the oncology space, investors may like this aggressive approach, especially from a company that has long been criticized for lack of d
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at Bank of America Corporation from $17.00 to $26.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcus Biosciences to Participate in Two Upcoming Investor ConferencesBusiness Wire
- Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported Earnings, And Analysts Cut Their Target Price [Yahoo! Finance]Yahoo! Finance
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockBusiness Wire
RCUS
Earnings
- 8/6/25 - Beat
RCUS
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- 12/1/25 - Form 4
- RCUS's page on the SEC website